CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (NASDAQ:CERS) announced today that it has received CE Mark approval to extend the platelet treatment range of its INTERCEPT Blood System, resulting in enhanced compatibility with all commonly used platelet collection methods, and in particular with practices prevalent in Eastern Europe, the Middle East and Africa. Many blood centers in these regions have not yet introduced the use of platelet storage solutions, which previously was necessary for use of the INTERCEPT treatment system.
